Review article: The clinical role of anti-TNFα antibody treatment in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 5, 2000, Pages 501-514

  Bell, S J ^a   Kamm, M A ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; AUTACOID; AUTOANTIBODY; AZATHIOPRINE; CYCLOSPORIN; DNA ANTIBODY; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; PREDNISOLONE; STEROID; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ANTIBODY PRODUCTION; ANTIGEN BINDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG COST; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; ENTEROPATHY; GENETIC ENGINEERING; HEADACHE; HEPATITIS; HOT FLUSH; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; INFECTION; INTESTINE FISTULA; KIDNEY FAILURE; LYMPHOMA; META ANALYSIS; NAUSEA; NEUROTOXICITY; NONHUMAN; PANCREATITIS; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SKIN TOXICITY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; COST-BENEFIT ANALYSIS; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034062016     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00777.x     Document Type: Review

References (84)

1. 1 Co MS, Queen C. Humanized antibodies for therapy. Nature 1991; 351: 501-2.
2. 2 Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-7.
3. 3 Brown PSJ, Parenteau GL, Dirbas FM, et al. Anti-Tac-H, a humanized antibody to the interleukin-2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 1991; 88: 2663-7.
4. 4 Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-53.
5. 5 Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-9.
6. 6 Wagner C, Mace K, deWoody K, et al. Infliximab treatment benefits correlate with pharmacodynamic parameters in Crohn's disease patients. Digestion 1998; 59(Suppl. 3): 124-5.
7. 7 Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22-8.
8. 8 Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159: 6276-82.
9. 9 Hommes DW, van Dullemen HM, van der Levi MEA, Woody J, Tytgat GN, et al. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease. Haemostasis 1998; 27: 269-77.
10. 10 Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996; 156: 1646-53.
11. 11 Paleolog E. Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis. Mol Pathol 1997; 50: 225-33.
12. 12 Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 1997; 36: 643-50.
13. 13 Pender SL, Fell JM, Chamow SM, Ashkenazi A, MacDonald TT. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998; 160: 4098-103.
14. 14 Hove T, van Deventer SJH. Anti-TNF antibody cA2 induces apoptosis in CD3/CD28 stimulated Jurkat cells: a potent immunomodulating mechanism. Gastroenterology 1999; 116: A739(Abstract).
15. 15 Targan S, Schaible T. Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1998; 338: 333-4.
16. 16 Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999; 5: 119-33.
17. 17 Redl H, Schlag G. Paul E, et al. Endogenous modulators of TNF and IL-1 response are under partial control of TNF in baboon bacteremia. Am J Physiol 1996; 271: R1193-8.
18. 18 Suitters AJ, Foulkes R, Opal SM, et al. Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock. J Exp Med 1994; 179: 849-56.
19. 19 Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease [see comments]. Lancet 1997; 349: 521-4.
20. 20 Sandborn WJ, Targan S, Wolf SB, et al. A randomized, double-blind, placebo-controlled, multi-centre trial of the engineered human antibody to TNF (CDP571) for the induction and maintenance of clinical improvement in patients with moderate to severely active Crohn's disease. Gut 1999; 4(Suppl. V): A133(Abstract).
21. 21 van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
22. 22 Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
23. 23 Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease [in process citation]. Gastroenterology 1999; 117: 761-9.
24. 24 Kam L, Vasiliauskas EA, Landers CJ, Targan S. magnitude of response to remicade correlates with marker antibody expression. Gastroenterology 1999; 116: A744(Abstract).
25. 25 D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116: 1029-34.
26. 26 Williams DR, Coller JA, Corman ML, Nugent FW, Veidenheimer MC. Anal complications in Crohn's disease. Dis Colon Rectum 1981; 24: 22-4.
27. 27 Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A [see comments]. Am J Gastroenterol 1993; 88: 646-9.
28. 28 Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997; 92: 876-9.
29. 29 Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-7.
30. 30 Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
31. 31 D'Haens G, Rutgeerts PJ, van Deventer SJH, et al. Repeated infusions of anti TNF alpha chimeric antibody (cA2) maintain remission in refractory Crohn's disease. Gut 1997; 41(Suppl. 3): A68-A69(Abstract).
32. 32 Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis [see comments]. Arthritis Rheum 1998; 41: 1552-63.
33. 33 Baert FJ, Rutgeerts PR. Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int J Colorectal Dis 1999; 14: 47-51.
34. 34 Hanauer SB, Rutgeerts P, D'Haens G, et al. Delayed hypersenstivity to Infliximab (Remicade) re-infusion after a 2-4 year interval without treatment. Gastroenterology 1999; 116: A731(Abstract).
35. 35 Rezaian MM. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Comment on the article by Maini et al. [letter]. Arthritis Rheum 1999; 42: 1779-81.
36. 36 Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999; 117(6): 1433-7.
37. 37 Greenstein AJ, Mullin GE, Strauchen JA, et al. Lymphoma in inflammatory bowel disease. Cancer 1992; 69: 1119-23.
38. 38 Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985; 56: 2914-21.
39. 39 Loftus EV, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Risk of lymphoma in inflammatory bowel disease: a population based estimate. Gastroenterology 1998; 114: A1024(Abstract).
40. 40 Bernstein CN, Kliewer E, Rawsthorne P, Doig W, Balnchard JF. Diagnoses of extraintestinal manifestations and cancers in IBD in large population based databases. Gastroenterology 1998; 114: A930(Abstract).
41. 41 Arseneau KO, Stukenborg GJ, Connors AF, Cominelli F. The incidence of non-Hodgkin's lymphoma in hospitalised Crohn's disease patients in Virginia - an administrative database study. Gastroenterology 1999; 116: A664(Abstract).
42. 42 Connell WR, Sheffield JP, Kamm MA, Ritchie JK, Hawley PR, Lennard-Jones JE. Lower gastrointestinal malignancy in Crohn's disease. Gut 1994; 35: 347-52.
43. 43 Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-52.
44. 44 Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-8.
45. 45 Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-42.
46. 46 Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 1273-6.
47. 47 Summers RW, Switz DM, Sessions JT Jr. et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-69.
48. 48 Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl 1998; 225: 92-9.
49. 49 Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine [see comments]. Lancet 1996; 347: 215-9.
50. 50 D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease [see comments]. Gastroenterology 1997; 112: 1475-81.
51. 51 Barbe L, Marteau P, Lemann M, et al. Dose raising of azathioprine beyond 2.5 mg/kg/day in Crohn's disease patients who fail to improve with a standard dose. Gastroenterology 1998; 114: A925(Abstract).
52. 52 Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years experience. Gut 1993; 34: 1081-5.
53. 53 Hoover R, Fraumeni JF Jr. Risk of cancer in renal-transplant recipients. Lancet 1973; 2: 55-7.
54. 54 Larvol L, Soule JC, Le Tourneau A. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease [letter]. N Engl J Med 1994; 331: 883-4.
55. 55 Vandeputte L, D'Haens G, Baert F, Rutgeerts P. Methotrexate in refractory Crohn's disease. Inflamm Bowel Dis 1999; 5: 11-5.
56. 56 Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators [see comments]. N Engl J Med 1995; 332: 292-7.
57. 57 Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results [see comments]. Mayo Clin Proc 1996; 71: 69-80.
58. 58 Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 1994; 20: 513-28.
59. 59 Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevarum HS, Baker AL. Is long term methrexate (MTX) use hepatotoxic in inflammatory bowel disease (IBD) patients. Gastroenterology 1999; 116: A830(Abstract).
60. 60 Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators [see comments]. N Engl J Med 1994; 330: 1846-51.
61. 61 Baker K, Jewell DP. Cyclosporin for the treatment of severe inflammatory bowel disease [published erratum appears in Aliment Pharmacol Ther 1989; 3: 414]. Aliment Pharmacol Ther 1989; 3: 143-9.
62. 62 Stange EF, Fleig WE, Rehklau E, Ditschuneit H. Cyclosporin A treatment in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1387-92.
63. 63 Brynskov J, Binder V, Riis P, et al. Low-dose cyclosporin for Crohn's disease: implications for clinical trials [see comments]. Aliment Pharmacol Ther 1989; 3: 135-42.
64. 64 Brynskov J, Freund L, Norby RS, et al. Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol 1991; 26: 689-95.
65. 65 Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases [see comments]. N Engl J Med 1992; 326: 1654-60.
66. 66 Ballardie FW, Winearls CG, Williams G. Cyclosporin and steroids in renal transplantation: risk of Pneumocystis carinii pneumonia? [Letter]. Lancet 1984; 2: 638-9.
67. 67 Markus MB. Cyclosporin A and Pneumocystis pneumonia [letter]. Med J Aust 1985; 143(2): 91.
68. 68 Peltekian KM, Williams CN, MacDonald AS, et al. Open study of cyclosporin A in patients with severe Crohn's disease refractory to conventional therapy. Can J Gastroenterol 1988; 2: 5-11.
69. 69 Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy [see comments]. N Engl J Med 1994; 330: 1841-5.
70. 70 Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994; 39: 374-80.
71. 71 Zeeh JM, Riley NE, Hoffmann P, Goebell H, Gerken G. Mycophenolate mofetil inhibits growth and expression of extracellular matrix in human intestinal and rat colonic smooth muscle cells. Gastroenterology 1999; 116: A948(Abstract).
72. 72 Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease [see comments]. Gut 1999; 44: 625-8.
73. 75 Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49-57.
74. 74 Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548-61.
75. 75 Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995; 155: 5038-45.
76. 76 Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [see comments]. N Engl J Med 1997; 337: 141-7.
77. 77 Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
78. 78 Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [see comments]. N Engl J Med 1999; 340: 253-9.
79. 79 Dalum I, Butler DM, Jensen MR, et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 1999; 17: 666-9.
80. 80 Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease [see comments]. Gut 1997; 40: 470-4.
81. 81 Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391-4.
82. 82 Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996; 35: 969-79.
83. 83 Wedel S, Bauditz J, Suk A, Lochs H. Efficacy of Thalidomide in Crohn's Disease. Gastroenterology 1999; 116: 3665(Abstract).
84. 84 Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease [see comments]. Gastroenterology 1999; 117: 1278-87.